| Abstract | We conducted a one-year comparative study of 25 patients with corticosteroid-induced osteoporosis associated with diffuse connective tissue disease. The patients were randomly divided into 2 groups: group A (9 patients), monotherapy with active vitamin D3 (V.D3); and group B (16 patients), combination therapy with V.D3 and etidronate. Four markers were employed: as an bonegenic marker, serum alkaline phosphatase (ALP); as a bone resorption marker, urinary deoxypyridinoline (DPD); as a bone salt minerals assay level, young adult mean (YAM); and bonefracture ratio. Results showed that: ALP decreased in both groups with no significant difference between groups; DPD increased significantly from baseline (p < 0.05) in group A, but it decreased significantly from baseline (p < 0.05) in group B, but again without a significant difference between groups; YAM resulted in no significant improvement in group A, but a significant improvement from baseline (p < 0.01) was shown in group B, with a significant difference between groups (p < 0.05); and a new spinal compression fracture ratio was extremely lower in group A than in group B. The findings indicated cyclical/intermittent etidronate therapy is effective in preventing corticosteroid-induced osteoporosis. |
| Authors | Y Jinnouchi
(Affiliation: Department of Medicine, Kurume University School of Medicine, Japan.)
|
| Journal | The Kurume medical journal
(Kurume Med J)
Vol. 47
Issue 3
Pg. 219-24
( 2000)
ISSN: 0023-5679 JAPAN |
| PMID | 11059223
(Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)
|
| Chemical References |
- Adrenal Cortex Hormones
- Etidronic Acid
|
| Topics |
- Adrenal Cortex Hormones
(adverse effects)
- Aged
- Connective Tissue Diseases
(chemically induced, drug therapy)
- Drug Administration Schedule
- Etidronic Acid
(administration & dosage, therapeutic use)
- Female
- Humans
- Male
- Middle Aged
- Osteoporosis
(chemically induced, drug therapy)
|
